tirzepatide naion risk Is (a GIP/GLP‑1 dual agonist) safe to initiate in a patient with a history of anterior ischemic optic neuropathy (AION) or other factors for optic nerve ischemia? Clinical studies have found that
Description
241 DPP-4 cleaves GLP-1(7-36) at the 8th position, generating GLP-1(936)
Risk of suicide, hair loss, and aspiration with GLP1-Receptor agonists and other diabetic agents: a real-world pharmacovigilance study
Ideally, it should be stored between 1530C, away from heat and humidity prevalent in many Australian households

For many patients, the cardiovascular, metabolic, and quality of life benefits outweigh the manageable risks to oral health

- Side effects often begin to lessen
